CLN - Industry Playbook

America’s Choice Provider Network to Cover Exosome Diagnostics’ Prostate Cancer Test

Industry Playbook: March 2018

Exosome Diagnostics has entered a preferred provider network agreement with America’s Choice Provider Network (ACPN) based in Henderson, Nevada, and Farmington Hills, Michigan. Under the terms of the agreement, more than 28 million ACPN members across the U.S. will gain access to and coverage for ExoDx Prostate(IntelliScore), or EPI, the company’s urine test that is intended to help prevent unnecessary prostate biopsies. EPI is designed for use in men 50 years of age or older who have a prostate-specific antigen result of 2-10 ng/mL and are presenting for an initial biopsy. The test detects three genetic biomarkers that indicate how aggressive a prostate tumor is. Along with clinical assessment and a patient’s medical history, EPI’s results help healthcare providers identify which patients in this subset do not have high-grade prostate cancer and who might be able to continue with monitoring instead of undergoing biopsy. Exosome Diagnostics offers EPI as a laboratory-developed test at the company’s CLIA-certified lab.

Advertisement
Advertisement